Phase 2 N=7 Thalidomide Low Threshold in Epilepsy
Refractory Epilepsy
Primary: Change From Baseline in the Mean Number of Daily Seizures at 1 Year. — 9 Number of Seizures — p=<0.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=11 Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS)
Epilepsies, Partial
Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants
Phase 3 N=240 RNS® System Pivotal Study
Epilepsy
Primary: Acute SAE Rate — 12.0 percentage of subjects with ≥ 1 SAE
N/A N=12,386 Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001
Phase 2 N=55 A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
Highly Drug-resistant Focal Epilepsy
Primary: 75 % Responder Rate During the 2-week Inpatient Period — 11.1; 30.8 percentage of participants — p==0.0679
Phase 2 N=21 A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
Refractory Partial Seizures
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Perampanel — 21; 11…
Phase 3 N=132 A Study With SAGE-547 for Super-Refractory Status Epilepticus
Super-Refractory Status Epilepticus
Primary: Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥…
N/A N=3 Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
Mesial Temporal Lobe Epilepsy
Primary: Safety and Tolerability of Low Frequency Stimulation of the Fornix With Regards to Memory Function — 0; 0 Participants
Phase 2 N=30 An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)
Refractory Partial Seizures
Primary: Maximum Tolerated Dose (MTD) — 0; 2; 1; 6 Participants
N/A N=5 Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation
Epilepsy, Temporal Lobe
Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks
Phase 2 N=48 Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures
Epilepsy
Primary: Percentage of Responders During the Maintenance Phase — 44.4; 34.2; 55.6; 65.8 Percentage of Participants
Phase 2 N=70 RNS® System Feasibility Study
Epilepsy
Primary: Acute SAE Rate — 6.2 percentage of participants
Phase 3 N=306 Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
Seizures
Primary: Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)…
Phase 3 N=539 Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
Seizures
Primary: Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)…
Phase 3 N=234 Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
Seizures · Epilepsies, Partial · Epilepsy, Complex Partial
Primary: Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile) — 5.92; NA Hours — p=0.012
Phase 2 N=25 Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Super-refractory Status Epilepticus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 17; 6 Participants
Phase 4 N=343 Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures
Epilepsy
Primary: Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational…
N/A N=17 Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy
Focal Epilepsy
Primary: Intensity of the MRI Signal in the Left Temporal Precentral Zone — 1.06; 1.04 ratio
Phase 3 N=356 Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
Epilepsy
Primary: Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase — -23.25; -9.80 Percentage change
Phase 3 N=249 Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
Epilepsy
Primary: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. — 39.5; 21.65 Percent…
Phase 3 N=653 Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
Partial Epilepsy
Primary: Seizure Frequency Over the 12-week Maintenance Period. — 7.88; 6.54; 6.00 Nº Standardized Seizures by 4 weeks — p=0.058
Phase 3 N=304 Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
Partial Epilepsy in Children and Adolescents
Primary: Change From Baseline in Seizure Frequency — 62.0; 36.6 seizures/month — p=0.2490
Phase 3 N=712 Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Refractory Partial Seizures
Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -10.69; -13.63; -23.33; -30.80…
N/A N=17 High Frequency Oscillation in Pediatric Epilepsy Surgery
Pediatric Epilepsy · Epilepsy Surgery · High Frequency Oscillation
Primary: Post-operative Seizure-free Rate — 4; 5; 4; 4 Participants
Phase 3 N=478 Established Status Epilepticus Treatment Trial
Benzodiazepine Refractory Status Epilepticus
Primary: Number of Participants With Clinical Cessation of Status Epilepticus - Intention to Treat — 53; 56; 68 Participants
N/A N=60 Neocortical Epilepsies - Do They Progress?
Epilepsy
Primary: Functional Connectivity
Phase 3 N=253 Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
Partial Epilepsy
Primary: Seizure Frequency — 7.3; 5.7; 5.5 ln (Seizures) per 4 weeks
Phase 3 N=323 Once-A-Day Pregabalin For Partial Seizures
Partial Seizures · Epilepsies, Partial
Primary: Log Transformed (Loge) 28-day Seizure Rate for All Partial Onset Seizures During the Double-blind Treatment Phase — 2.24; 2.33; 2.32; 1.84 ln (seizures per 28 days)…
Phase 3 N=389 To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Refractory Partial Seizures
Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -9.72; -30.52; -17.57 Percent Change
Phase 2 N=39 Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
Schizophrenia
Primary: Response Rates in the ECT Plus Clozapine Group vs the Pharmacotherapy Group. — 50; 0 Percentage of responders